Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518

被引：0
|
作者：
Rosenstock, Julio [1 ]
机构：
[1] Dallas Diabet Res Ctr, Dallas, TX 75230 USA
来源：
DIABETES CARE | 2021年 / 44卷 / 11期
关键词：
GLARGINE;
D O I：
10.2337/dci21-0004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E196 / E197
页数：2
相关论文
共 50 条
  • [21] Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?
    Liatis, S.
    Makrilakis, K.
    DIABETES OBESITY & METABOLISM, 2014, 16 (03): : 284 - 284
  • [22] Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials
    Wang, Y.
    Li, L.
    Yang, M.
    Liu, H.
    Boden, G.
    Yang, G.
    DIABETES OBESITY & METABOLISM, 2011, 13 (11): : 972 - 981
  • [23] Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes
    Shimodaira, M.
    Muroya, Y.
    Kumagai, N.
    Tsuzawa, K.
    Honda, K.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2013, 36 (09): : 734 - 738
  • [24] Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes
    M. Shimodaira
    Y. Muroya
    N. Kumagai
    K. Tsuzawa
    K. Honda
    Journal of Endocrinological Investigation, 2013, 36 : 734 - 738
  • [25] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
  • [26] Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes
    Hirsch, Irl B.
    Parkin, Christopher G.
    Cavaiola, Tricia Santos
    Bergenstal, Richard M.
    DIABETES OBESITY & METABOLISM, 2024, 26 : 17 - 26
  • [27] A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes
    Baxter, Mike
    Morimoto, Yukiko
    Tamiwa, Masami
    Hattori, Masakatsu
    Peng, Xuejun Victor
    Lubwama, Robert
    Maegawa, Hiroshi
    DIABETES THERAPY, 2020, 11 (07) : 1481 - 1496
  • [28] A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes
    Mike Baxter
    Yukiko Morimoto
    Masami Tamiwa
    Masakatsu Hattori
    Xuejun Victor Peng
    Robert Lubwama
    Hiroshi Maegawa
    Diabetes Therapy, 2020, 11 : 1481 - 1496
  • [29] Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis
    Liu, Fu-peng
    Dong, Jian-jun
    Yang, Qing
    Xue, Xian-zhong
    Ren, Zhong-fa
    Gan, Yi-zhang
    Liao, Lin
    JOURNAL OF DIABETES, 2015, 7 (03) : 322 - 328
  • [30] Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
    Hinnen, Deborah
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S4 - S11
12345